The estimated Net Worth of Neil Abdollahian is at least $1.5 Milión dollars as of 5 January 2021. Mr. Abdollahian owns over 4,337 units of Cidara Therapeutics Inc stock worth over $667,813 and over the last 8 years he sold CDTX stock worth over $37,839. In addition, he makes $796,475 as Chief Business Officer at Cidara Therapeutics Inc.
Neil has made over 4 trades of the Cidara Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,337 units of CDTX stock worth $9,802 on 5 January 2021.
The largest trade he's ever made was selling 7,284 units of Cidara Therapeutics Inc stock on 1 October 2019 worth over $14,422. On average, Neil trades about 1,162 units every 48 days since 2016. As of 5 January 2021 he still owns at least 57,471 units of Cidara Therapeutics Inc stock.
You can see the complete history of Mr. Abdollahian stock trades at the bottom of the page.
Neil Abdollahian serves as Chief Business Officer of the Company. He joined us as Chief Business Officer in July 2016. Previously, he served as Managing Director of Clarity Point Partners, a strategic advisory firm focused on managing corporate licensing efforts, product acquisitions and technology spin-outs for a number of biopharmaceutical companies. From 2008 to 2013, he served as Vice President of Corporate Development at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he led the corporate partnering initiatives that resulted in the Asia-Pacific and emerging markets strategic partnership with Bayer Healthcare, and ultimately, the acquisition by Cubist Pharmaceuticals in 2013. In 2008, Mr. Abdollahian served as Director of Special Projects in a biopharmaceutical focused investment bank in Sydney, Australia, and from 2001 to 2007, he held various business development positions focused on closing high-value transactions while at Avanir Pharmaceuticals, Isis Pharmaceuticals and Neurogen Corporation, each of which is a biopharmaceutical company. Mr. Abdollahian holds an MBA from Pepperdine University, an M.S. in the biomedical sciences from the University of New Mexico Medical School and a B.S. in biology from the George Washington University.
As the Chief Business Officer of Cidara Therapeutics Inc, the total compensation of Neil Abdollahian at Cidara Therapeutics Inc is $796,475. There are 2 executives at Cidara Therapeutics Inc getting paid more, with Jeffrey Stein having the highest compensation of $1,451,970.
Neil Abdollahian is 47, he's been the Chief Business Officer of Cidara Therapeutics Inc since 2016. There are 16 older and 2 younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Neil's mailing address filed with the SEC is C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR, STE 101, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio... a Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: